Oncolytics Biotech (ONCY) Expected to Announce Earnings on Thursday

Key Points

• Oncolytics Biotech is set to release its Q2 2025 earnings on August 7th, with analysts predicting an earnings per share of ($0.10) for the quarter.
• The company recently reported ($0.06) earnings per share for Q1 2025, surpassing expectations by $0.03, and has a market cap of $101.31 million.
• Analysts have a consensus rating of "Moderate Buy" for Oncolytics Biotech, with a target price of $4.33, and one firm has set a price target as high as $5.00.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.03. On average, analysts expect Oncolytics Biotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncolytics Biotech Stock Performance

Shares of NASDAQ ONCY traded down $0.03 during trading on Friday, reaching $0.99. The stock had a trading volume of 537,614 shares, compared to its average volume of 1,004,573. Oncolytics Biotech has a one year low of $0.33 and a one year high of $1.53. The stock has a market cap of $96.44 million, a PE ratio of -3.41 and a beta of 1.07. The firm's 50 day moving average price is $0.79 and its two-hundred day moving average price is $0.69.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ONCY. HC Wainwright reiterated a "buy" rating and issued a $5.00 price target on shares of Oncolytics Biotech in a report on Wednesday, May 21st. Jones Trading reiterated a "hold" rating on shares of Oncolytics Biotech in a report on Friday, May 16th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $4.33.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.